Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: CALGB 10701 Principal Investigator: Uy, Geoffrey
Title: A Phase II Study of Dasatanib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years with Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG, and SWOG
Phase: II Disease Site: Lymphoid Leukemia
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is find out what effects (good and bad) an experimental drug known as dasatinib has on patients and their leukemia.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)